Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific share transactions.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Transfers and receipts of shares for nil consideration.
- Transaction Price: £0.00 per share.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details three specific internal share movements:
- February 18, 2022: Ms. V. Whyte (Company Secretary) transferred 11,170 Ordinary Shares between accounts for nil consideration.
- February 23, 2022: Ms. V. Whyte transferred 11,344 Ordinary Shares to her spouse for nil consideration.
- February 23, 2022: Mr. I. Whyte (PCA of Ms. V. Whyte) received 11,344 Ordinary Shares from his spouse for nil consideration.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. It is a regulatory disclosure of insider share movements.
Investor Verification Checklist
- Verify that the reported transactions were non-monetary transfers (nil consideration) and did not involve open market sales or purchases.
- Confirm the total volume of shares moved (22,514 shares) relative to the company's total outstanding share count to assess materiality.
- Check subsequent filings to ensure these transfers were not part of a larger pattern of insider trading activity.